Implanet Subscribes to a Contingent Equity Line with Kepler Cheuvreux

Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces that it is taking out a contingent equity line with Kepler Cheuvreux, as authorized by its Shareholder Meeting.

"Implanet’s Board of Directors has approved its subscription to this equity financing solution, which is particularly suited to our international expansion strategy and which provides us with increased flexibility and guarantees. This contingent equity line will not be equated with an immediate cash requirement, but rather as additional security with regard to our financial structure, which is currently solid. This tool would thus allow us to minimize any dilutive effect on shareholders to the strict minimum at any given time. We have no drawdown obligation, and only intend to use this financing facility if it is in the best interest of the Company and its shareholders”, says Ludovic Lastennet, CEO of Implanet.

Implanet may ask Kepler Cheuvreux to subscribe to new shares that may be issued in tranches over the coming 24 months, up to a maximum of 530,000 shares or 9.81% of the Company’s current share capital. Kepler Cheuvreux has made a firm commitment to subscribe to these shares exclusively at Implanet’s request.

For each tranche, the issuance price will depend on the average prevailing share price discounted by no more than 6%. This discount will enable Kepler Cheuvreux, who is a financial intermediary and has no intention of remaining a shareholder in the Company, to underwrite the subscription regardless of market volatility.

Should the entire contingent equity line be drawn upon¹, a shareholder who currently owns 1% of the Company’s share capital would see his or her share ownership reduced to 0.91%².

Next financial press release: revenue for the 1^st half of 2014, on 28 July, 2014

About IMPLANET
Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. IMPLANET’s proven orthopedic platform, based on perfectly controlling the traceability of its products, gives the Company the proven ability to enhance this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory approval from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 38 staff and recorded 2013 sales of €6.7 million.

For further information, please visit www.implanet.com

¹ Resulting in the issuance of 530,000 new shares
² Based on an Implanet share capital of 5,399,522 shares